

Application No.: 10/696,349  
Docket No.: PE0649 US DIV2

Page 7

### REMARKS

The above amendments and the below remarks are responsive to the Office Action, dated June 29, 2005, entered in the above referenced pending application. The pending claims are 12-21.

Each of the Examiner's rejections are addressed separately below.

#### Information Disclosure Statement

A supplemental Information Disclosure Statement is being filed concurrently herewith to include the month and year of the publications indicated by the Examiner as not being considered.

#### Rejections under 35 U.S.C. § 103

1. WO 01/41512 and Polymer Preprints 41(1), 2000, pp. 770-771

Claims 13-15 and 17-21 were rejected under 35 U.S.C. § 103(a) as being unpatentable over WO 01/41512 ("*Thompson*") in view of the article by Djurovich et al., Polymer Preprints 41(1), 2000, pp. 770-771 ("*Djurovich*"). Applicants respectfully traverse this rejection

Claims 13-15 and 17 (compound claims) and 18-20 (device claims)

It is respectfully submitted that *Thompson* does not teach or suggest compounds having the specific compounds of Claims 13-15 and 17-21. While *Thompson* discloses devices having an emitting layer comprising a compound  $L_2MX$ , where L and X are bidentate ligands and M is an octahedral metal, such as iridium and further discloses that the L ligand can have a phenylisoquinoline structure, which is labelled as "arylquinoline", in Figure 39, such is not a teaching or suggestion of the pending subject matter. In particular, *Thompson* does not teach or suggest compounds having the specific phenylisoquinoline ligands recited in Applicants' Claims 13-15 and 17-19. *Thompson* indicates the possibility of substituents on the aromatic rings of the "arylquinoline" ligand in Figure 39. However, there is no teaching or suggestion of what these substituents could or should be.

*Djurovich* does not complete the deficiencies of the *Thompson* reference. *Djurovich* teaches only one compound, an iridium complex having three phenylpyridine ligands, substituted with fluorine ("Flrppy"). The Examiner further stated that it would have been obvious to use the fluorine of Flrppy as the substituents on the "arylquinoline" ligand of *Thompson* in order to improve the solubility. Applicants respectfully disagree with this assessment. The ligand of the *Djurovich* complex is a phenylpyridine, not a phenylquinoline or phenylisoquinoline. While *Djurovich* indicates that the substitution of fluorines on the phenylpyridine ligand increases the solubility of the complex in organic solvents, the

Application No.: 10/696,349  
Docket No.: PE0649 US DIV2

Page 8

reference also indicates that the emission efficiency is decreased. *See Djurovich* at paragraph bridging pages 770 and 771. It is respectfully submitted that one of ordinary skill reading *Djurovich* would not have chosen fluorine as a substituent on a phenylisoquinoline ligand. The Examiner noted that *Thompson* and *Djurovich* are common inventor/authors on the two references. Applicants submit that the common inventership/authorship is evidence that the combining of *Thompson* and *Djurovich* actually teaches away from the subject matter of Claims 13-15 and 17. Specifically, the *Thompson* reference teaches away from use of fluorine substituents. Since both *Thompson* and *Djurovich* were aware of fluorine as a possible substituent in the world of general chemistry, if it was in any way of interest to them, such a substituent would have mentioned it if it were suitable for the "arylquinoline" ligand of *Thompson*. The failure to list fluorine as a substituent is an indication to one of ordinary skill against its use. Furthermore, neither reference teaches or suggests trifluoromethyl substituents on any type of ligand.

The specific compounds are neither taught nor suggested and thusly, their use in an electronic device (Claims 18-20) is neither taught nor suggested.

Applicants respectfully request that this rejection be withdrawn with respect to Claims 13-15 and 18-20.

#### Claim 21

The Examiner stated that it would have been obvious to use greater than 20% by weight of the iridium complex in the light-emitting layer of *Thompson* in order to increase the total amount of light emitted. Applicants respectfully disagree with this conclusion. *Thompson* does not teach a range of concentrations for an iridium complex in a light-emitting layer. *Thompson* discloses one data point: a device in which the light-emitting layer is 12% by weight bis(2-phenylbenzothiazole)iridium acetylacetonate ("BTIr") in 4,4'-N,N'-dicarbazole-biphenyl. The BTIr complex does not have a ligand with Applicants' structure (XI) or (XII) as recited in Claim 26. *Djurovich* teaches that devices with maximum efficiency are obtained with FIrppy concentrations in the range of 2.5-3.5 wt%. (*see* last paragraph on page 771) Again, the FIrppy complex does not have a ligand with Applicants' structure (XI) or (XII) as recited in Claim 21, nor does it have the ligand in the BTIr complex of *Thomson*. The *Thompson* and *Djurovich* references taken individually or collectively do not teach any concentration range for iridium complexes having a ligand with Applicants' structure (XI) or (XII), as recited in Claim 21. If anything, the combined references teach that the concentration of an iridium complex in a light-emitting layer should be 12 wt% or lower.

Applicants respectfully request that this rejection be withdrawn with respect to Claim 21.

2. WO 01/41512; Inorganic Chemistry, Vol. 30, 1991, 1685-1687; and

Application No.: 10/696,349  
Docket No.: PE0649 US DIV2

Page 9

WO 00/70655

Claims 12-21 were rejected under 35 U.S.C. § 103(a) as being unpatentable over WO 01/41512 ("*Thompson*") in view of the Dedeian et al. article Inorganic Chemistry, Vol. 30, 1991, 1685-1687 ("*Dedeian*") and WO 00/70655 ("*Baldo*"). Applicants respectfully traverse this rejection.

Claims 12-17

As noted above, *Thompson* does not teach or suggest compounds having the specific phenylisoquinoline ligands recited in Applicants' Claims 12-17. *Thompson* indicates the possibility of substituents on the aromatic rings of the "arylquinoline" ligand in Figure 39. However, there is no teaching as to what these substituents could or should be. *Thompson* teaches in the paragraph bridging pages 34 and 35, that in  $L_2MX$  complexes, the X ligand can, in some cases, affect the energy of emission and efficiency. There is no suggestion that substituents on the L ligand can be used to tune the color.

Application No.: 10/696,349  
Docket No.: PE0649 US DIV2

Page 10

The Examiner has pointed to *Dedeian* to provide the substituents for the complexes of *Thompson*. *Dedeian* discloses iridium complexes having three substituted 2-phenylpyridine ligands ("tris complexes") as strong photoreducing agents. The complexes of *Dedeian* have substituents on the phenyl group in the phenylpyridine ligand, *i.e.*, 4-fluorophenyl and 4-trifluoromethylphenyl. (see Table I at the top of page 1686) There is no suggestion in *Dedeian* to use such substituents in any system other than a tris complex with phenylpyridine. The Examiner has further pointed out that the *Thompson* and *Dedeian* references share a common author. Applicants submit that because of this, the *Thompson* reference teaches away from trifluoromethyl substituents. Since the inventors in *Thompson* were aware of trifluoromethyl as a substituent, they surely would have mentioned it if it were suitable for the phenylisoquinoline ligands of *Thompson*. The failure to list fluoroalkyl or trifluoromethyl as a substituent is an indication against its use.

The addition of the teachings of the *Baldo* reference does not overcome the deficiency. *Baldo* discloses tris complexes with phenylpyridine ligands ("Ir(ppy)<sub>3</sub>") and teaches that substituents on either ring can be alkyl or aryl. No substituted ligands are exemplified. The teaching of *Baldo* on pages 14 and 15, refers to the different properties of tris complexes with different ligands, *i.e.*, phenylpyridine, phenylpyrimidine, and bipyridine ligands. There is no suggestion of other ligands, and certainly no suggestion of other substituted ligands. Based on the combined teachings of *Thompson*, *Dedeian*, and *Baldo*, and absent Applicants' teaching, one of ordinary skill in the art would not know to use fluoro or trifluoromethyl substituents on a phenylisoquinoline ligand and arrive at the compounds recited in Claims 12-17.

Applicants respectfully request that the rejection be withdrawn with respect to Claims 12-17.

#### Claims 18-20

With respect to Claims 18-20, Applicants respectfully submit that electronic devices comprising the compounds of Claims 12-17 are not taught or suggested by *Thompson*, *Dedeian*, and *Baldo*, for all the reasons enumerated above.

Applicants respectfully request that the rejection be withdrawn with respect to Claims 18-20.

#### Claim 21

As noted above, *Thompson* does not teach a range of concentrations for an iridium complex in a light-emitting layer. *Thompson* discloses one data point: a device in which the light-emitting layer is 12% by weight bis(2-phenylbenzothiazole)iridium acetylacetonate ("BTIr") in 4,4'-N,N'-dicarbazole-biphenyl. The BTIr complex does not have a ligand with Applicants' structure (XI) or (XII) as recited in Claim 26. *Dedeian* relates to the use of the

Application No.: 10/696,349  
Docket No.: PE0649 US DIV2

Page 11

iridium complexes as photoreducing agents and does not discuss electronic devices at all. *Baldo* teaches in Figure 2 that with iridium complexes having three phenylpyridine ligands, the efficiency of devices drops dramatically when the emitting layer has more than 6%  $\text{Ir(ppy)}_3$ . The *Thompson*, *Dedeian*, and *Baldo* references taken individually or collectively do not teach any concentration range for iridium complexes having a ligand with Applicants' structure (XI) or (XII), as recited in Claim 21. If anything, the combined references teach that the concentration of an iridium complex in a light-emitting layer should be 12 wt% or lower.

Applicants respectfully request that this rejection be withdrawn with respect to Claim 21.

#### Conclusion

In view of the foregoing remarks, Applicants respectfully submit that the above referenced pending application is in condition for allowance. A Notice of Allowance for Claims 12-21 is therefore earnestly solicited.

Respectfully submitted,



MARY ANN CAPRIA  
ATTORNEY FOR APPLICANTS  
Registration No.: 32,659  
Telephone: (302) 992-3749  
Facsimile: (302) 892-7949

Dated: 9/29/2005

SEP 29 2005

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:

VLADIMIR GRUSHIN ET. AL.

CASE NO.: PE0649 US DIV2

APPLICATION NO.: 10/696,349

CONFIRMATION NO.: 6624

GROUP ART UNIT: 2813

EXAMINER: ERIK J. KIELIN

FILED: October 29, 2003

FOR: ELECTROLUMINESCENT IRIIDIUM COMPOUNDS WITH FLUORINATED  
PHENYLPYRIDINES, PHENYLIRIMIDENES, AND PHENYLQUINOLINES  
AND DEVICES MADE WITH SUCH COMPOUNDS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants file this Supplemental Information Disclosure Statement to provide the month and year of the non-patent document publications. The documents were previously provided. Enclosed is the PTO/SB/08B.

Should any to fee be required in connection with the filing of this Information Disclosure Statement please charge such fee to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Respectfully submitted,



MARY ANN CAPRIA  
Attorney for Applicants  
Registration No.: 32,659  
Telephone: (302) 992-3749  
Facsimile: (302) 892-7949

Dated: 9/29/2005  
Enclosures

PTO/SB/085 (08-03)

Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/896,348
		Filing Date	October 28, 2003
		First Named Inventor	VLADIMIR GRUSHIN ET. AL.
		Group Art Unit	2813
		Examiner Name	UNKNOWN
Sheet 1 of 1	Attorney Docket Number	PE0849USDIV2	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LAMANSKY, SERGEY ET AL., Highly Phosphorescent Bis-Cyclometalated Iridium Complexes: Synthesis, Photophysical Characterization, and Use in Organic Light Emitting Diodes, J. Am. Chem. Soc., 04/13/2001, 4304-4312, 123, American Chemical Society	<input type="checkbox"/>
		LAMANSKY, SERGEY ET AL., Synthesis and Characterization of Phosphorescent Cyclometalated Iridium Complexes, Inorg. Chem. 03/01/2001, 1704-1711, 40, American Chemical Society	<input type="checkbox"/>
		LAMANSKY, SERGEY ET AL., Molecularly doped polymer light emitting diodes utilizing phosphorescent Pt(II) and Ir(III) dopants, Organic Electronics, March 2001, 53-62, 2, Elsevier Science B.V.	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.